Unique ID issued by UMIN | UMIN000041262 |
---|---|
Receipt number | R000047120 |
Scientific Title | Observational study of SARS-CoV-2 antibody test positive rate. |
Date of disclosure of the study information | 2020/08/01 |
Last modified on | 2022/08/02 11:02:17 |
Observational study of SARS-CoV-2 antibody test positive rate.
Observational study of SARS-CoV-2 antibody test positive rate.
Observational study of SARS-CoV-2 antibody test positive rate.
Observational study of SARS-CoV-2 antibody test positive rate.
Japan |
SARS-CoV-2
Infectious disease |
Others
NO
Conduct a SARS-CoV-2 antibody test and calculate the test positive rate.
Examine the influence of volunteers' factors on the test positive rate
Others
Epidemiological
Exploratory
Pragmatic
SARS-CoV-2 antibody test positive rate.
Factors that influence on test positive rate
Observational
Not applicable |
Not applicable |
Male and Female
1, A subject, willing to take SARS-CoV-2 antibody test, gives written consent to the study.
1, A subject whose blood is difficult to collect.
2, A subject who the investigators think is not appropriate to the study.
4000
1st name | Shin |
Middle name | |
Last name | Irie |
SOUSEIKAI
CEO
813-0017
3-5-1 Kashiiteriha, Higashi-ku, Fukuoka
0926623551
junko-manabe@lta-med.com
1st name | Tatsuya |
Middle name | |
Last name | Yoshihara |
SOUSEIKAI Fukuoka Mirai Hospital
Clinical Research Center
813-0017
3-5-1 Kashiiteriha, Higashi-ku, Fukuoka
0926623608
tatsuya-yoshihara@lta-med.com
SOUSEIKAI
SOUSEIKAI
Other
Hakata Clinic Institutional Review Board
6-18 Tenyamachi, Hakata-ku, Fukuoka, Fukuoka
0922837701
miyako-koga@lta-med.com
NO
2020 | Year | 08 | Month | 01 | Day |
IJERPH | Free Full-Text | SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals an
Unpublished
IJERPH | Free Full-Text | SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals an
2160
IgG antibody positive rate was 1.2% in both Aug and Oct 2020, but excluding one facility where a nosocomial infection occurred in Apr, IgG antibody positive rate was 0.8% in both months. 21 of the 22 patients (95.5%) who were positive for IgG antibodies in Aug were also positive for IgG antibodies in Oct. Of the 28 patients who tested positive for IgG antibody at least once, 17 (60.7%) had symptoms suggestive of COVID-19 after Feb. 10 of 14 (71.4%) with a previous diagnosis of COVID-19 were IgG positive.
2022 | Year | 08 | Month | 02 | Day |
A total of 2160 SOUSEIKAI workers who was working in August and October 2020 was tested untibody test.
Oral and written explanations were given and written informed consent was obtained prior to testing
Not analyzed.
immunoglobulin (Ig)M and IgG antibodies
Completed
2020 | Year | 07 | Month | 21 | Day |
2020 | Year | 07 | Month | 31 | Day |
2020 | Year | 08 | Month | 01 | Day |
2020 | Year | 10 | Month | 22 | Day |
Conduct a SARS-CoV-2 antibody test mainly on staff within organisation.
2020 | Year | 07 | Month | 30 | Day |
2022 | Year | 08 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047120
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |